Q3: 2025-11-04 Earnings Summary
EPS of -$0.94 misses by $0.16
| Revenue of $2.76M (-26.12% Y/Y) misses by $20.79M
Kymera Therapeutics, Inc. (KYMR) UBS Global Healthcare Conference 2025 November 10, 2025 11:45 AM EST
Company Participants
Jared Gollob – Chief Medical Officer
Conference Call Participants
Xiaochuan Dai – UBS Investment Bank, Research Division
Presentation
Xiaochuan Dai
UBS Investment Bank, Research Division
All right. Well, thank you, everyone, for joining us in our fireside chat with Kymera Therapeutics. Yes, I’m told that if you have questions, you want to ask in the audience, please scan the QR code and then you’re able to ask a question, and then I will be able to pick it up here on the iPad and ask you questions. So please feel free to scan the QR code and then put your questions in there.
All right. With that out of the way, it’s our great pleasure to welcome Jared Gollob, Chief Medical Officer of Kymera. Jared, thank you for joining us.
Jared Gollob
Chief Medical Officer
Yes. Thanks, David. Thanks for having me.
Xiaochuan Dai
UBS Investment Bank, Research Division
That’s great.
Question-and-Answer Session
Xiaochuan Dai
UBS Investment Bank, Research Division
Well, for those probably new to the Kymera story, can you just give a quick overview of the company, your degrader platform and then any key assets that investors should pay attention to?
Jared Gollob
Chief Medical Officer
Sure, happy to. Yes. Next year, we’ll be celebrating — Kymera will be celebrating our 10th anniversary since we were founded by Nello Mainolfi and Bruce Booth. We were founded with protein degradation really as our platform, and really with the aim being to turn protein degradation into transformative drugs for diseases with high unmet need.
There’s been a real evolution over the past 10 years. Our platform itself has evolved considerably to the point now where we can really address very difficult-to-drug targets, transcription factors, multifunctional proteins almost
